CHFT has become the first Trust in the UK to introduce a new high-power Jena Surgical 150-watt Holmium Laser, which is a big step forward in the treatment of benign prostatic hyperplasia (BPH), a common condition affecting ageing men.

It means the team can offer High-Power Holmium Laser Enucleation of the Prostate (HoLEP), a state-of-the-art, minimally invasive procedure designed to remove excess prostate tissue and relieve urinary obstruction caused by BPH.

Mr Tahir Qayyum, Consultant Urological Surgeon, said: “This innovation represents a major leap forward in urological care. The HoLEP procedure allows for more complete removal of obstructive prostate tissue, with faster recovery times and fewer complications. With the advanced power and speed of the new Jena Surgical laser system and the all-in-one tissue morcellator, we can reduce operative times and anaesthetic exposure, enabling us to treat more patients effectively.”

Consultant Urological Surgeon, Yasir Hassanein, said: "This versatile laser technology also enables us to treat kidney stones with high precision and efficiency—further demonstrating its value across a range of urological procedures. Its introduction reinforces our Trust’s commitment to delivering world-class care through the adoption of the latest medical innovations."

The HoLEP service is being led by Consultants Nicholas Bryan and Tahir Qayyum, who were mentored in the technique by Mr Matthiew Liew, a highly experienced HoLEP surgeon from the NHS University Hospitals of Liverpool Group.

Pictured from left to right – Yasir Hassanein, Tahir Qayyum and Nicholas Bryan with visiting mentor Mathiew Liew.